Voriconazole
Find information on thousands of medical conditions and prescription drugs.

Voriconazole

Voriconazole (Vfend®, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These infections include invasive candidiasis and aspergillosis. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Administration

Oral (in tablets or suspension) or intravenous. Voriconzole interacts with many medications, including drugs given to suppress the immune system in transplant patients (e.g. cyclosporine, etc.).

Side effects

Common side effects include:

  • Blurred vision, increased eye sensitivity to light, or other visual changes
  • Nausea, vomiting, or diarrhea
  • Headache
  • Swelling or water retention.

Rare but life-threatening side effects include:

  • Severe liver damage
  • Allergic reactions to the medication

Read more at Wikipedia.org


[List your site here Free!]


Voriconazole for Candida Blood, deep tissue, and other infections
From Journal of Drugs in Dermatology, 3/1/05

The FDA has approved new indications for voriconazole injection, tablets, and oral suspension (VFEND, made by Pfizer, Inc.), expanding its use in the treatment of candidemia and candidal infections in non-neutropenic patients including disseminated skin infections. Voriconazole is a triazole anti-fungal agent. The primary mode of action of voriconazole is inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis.

The approval followed results from a randomized, comparative study involving 422 non-neutropenic patients with candidemia and clinical signs of infection. The study demonstrated that voriconazole was as effective as amphotericin B (followed by fluconazole) therapy in achieving a successful response, as defined by resolution or improvement of all clinical signs of infection at 3 months (41% for both). Median treatment time was 15 days.

The most frequently reported adverse events associated with therapy included visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, and respiratory disorders. Discontinuation of therapy was most commonly a response to elevated liver enzyme levels, rash, and visual disturbances.

Voriconazole has previously gained FDA-approval for the treatment of invasive aspergillosis, esophageal candidiasis, and as salvage therapy for fungal infections caused by Scedosporium apiospermum and Fusarium species pathogens.

COPYRIGHT 2005 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group

Return to Voriconazole
Home Contact Resources Exchange Links ebay